


Analysis of Future Treatments in Breast Cancer

Current And Future Therapy Overview

Breast cancer ranks as the second most frequently diagnosed cancer and is the predominant form of cancer affecting women. The FDA has granted approval for a greater number of breast cancer treatments compared to any other solid tumor. The drug landscape is constantly evolving, with ongoing research and development for new treatments. Current FDA approvals and research indicate a strong focus on combination therapies, showcasing a shift toward targeted therapies from chemotherapies.

CURRENT LANDSCAPE

In 1992, FDA made regulations to broaden clinical trial participation and expedite approvals. Since then, 34 drugs have been approved for treatment of breast cancer. The six drugs approved prior to that are mostly used in combination therapies.



- Treatment decisions for breast cancer are highly individualized and consider factors such as cancer stage, tumor characteristics, and patient preferences.
- In the past, approvals for combination therapies were more in drugs approved before the implementation of new regulations. Recently, the focus has shifted toward selective estrogen receptor degrader or downregulator (SERDs), cyclin-dependent kinase inhibitors, and PARP inhibitors as the mechanism of action, moving away from chemotherapy and aromatase inhibitor drugs.
- Tukysa, in combination with trastuzumab, received breakthrough status in 2023 for breast cancer treatment. Further, So far, 14 therapies have received orphan drug status
- However, the landscape is evolving, and in recent times, there has been a resurgence in both the approvals and trials of combination therapies.


Key players




FUTURE LANDSCAPE

Currently, there are around 1,512 trials underway for breast cancer. The anticipated expansion of novel therapies in the near-term pipeline may continue to change current standards of care and offer additional promising treatment options.


Trials are investigating breast cancer independently as well as in conjunction with other solid tumors.




Across the clinical pipeline, activity is focused on biomarkers or overall breast cancer in general. Trials are highest in Phase II ...



While most trials target all genders, ~514 trials specifically focus on female breast cancer.



...where HER2-negative breast cancer is witnessing high activity on account of high burden (~80 new cases/100,000 women).



Key players from pipeline	Number of trials
Astra Zeneca	60
Novartis	83
Pfizer	49
Eli Lilly	48
Roche	25
Glaxo Smith Kline	28
Sanofi	20

Promising therapies

- From Phase III trials, Camizestrant exhibits remarkable results for progression-free survival (20.3% at 150mg) compared to another approved drug (11.5%).
- Capiwasertib is also being extensively tested with other approved drugs fulvestrant and olaparib.
- Biomarker-driven clinical trials by Roche and Eli Lilly's pemetrexed have yielded promising results.
- There are more antibody-drug conjugates and monoclonal antibodies being tested with small molecules.

Overall, survival rates are on the rise and death rates are on the decline, primarily due to early detection, personalized treatment, and improved understanding. The latest breast cancer treatment trends focus on targeted, safer, and effective therapies that prioritize patient goals and outcomes. Remarkable opportunities arise from the latest research advancements that specifically target improving overall survival, combating historically treatment-resistant diseases, and minimizing disease progression.

Right from understanding key issues to advising you through the right set of insights and recommendations, Aranca Research, consolidation, and insightful analysis to aid in-depth understanding of therapy and effective decision-making

HOW CAN ARANCA HELP?

- 01 Epidemiological Analysis:** Prevalence and diagnosis of the diseases based on geography, gender, race and ethnicity, etc.
- 02 Diagnosis and Treatment Paradigm:** Analysis of diagnosis and treatment algorithm adopted in clinical practice
- 03 Current and Future Landscape:** Current treatments and latest pipeline landscape assessment for a particular therapy area
- 04 Humanistic, Economic Burden, and Unmet Need Analysis:** Impact of a disease on the patient's mental and economic well-being
- 05 Health Technology Assessment:** Analysis of various HTA decisions published by various countries

Connect with us



info@aranca.com



www.aranca.com/contact-us.php



www.linkedin.com/company/aranca